GLP-1 drug sales overtook generative AI revenue in 2025, Exponential View reports
Overview
GLP-1 drug sales reached $76 billion by the end of 2025, above the $63 billion in generative AI revenue that Exponential View estimates for the same period.
Exponential View reports that more than twice as many Americans pay for GLP-1 drugs as pay for AI, and that the share of US adults taking a GLP-1 for weight loss rose from 3% in 2024 to 11%.
Cash prices have fallen sharply. Exponential View reports that Novo's self-pay semaglutide price dropped to as low as $199 per month from February this year.
Written by AI from the articles below · updated Oct 12, 8:53 AM ET
Check the sources:
Article timeline
The articles in this story. Times are ET.
- Exponential ViewBlogGLP-1 drug sales overtook generative AI revenue in 2025, Exponential View reports
AIGLP-1 sales reached $76 billion by the end of 2025, exceeding the $63 billion generative AI revenue Exponential View estimates for the same period. More than twice as many Americans pay for GLP-1s as pay for AI, and the share of US adults taking a GLP-1 for weight loss rose from 3% in 2024 to 11%. Cash prices have fallen sharply, with Novo's self-pay semaglutide price dropping to as low as $199 per month from February this year.
Heat trend
Not enough continuous observations to show a trend yet.